Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells

Standard chemotherapy is the only systemic treatment for triple-negative breast cancer (TNBC), and despite the good initial response, resistance remains a major therapeutic obstacle. Here, we employed a High-Throughput Screen to identify targeted therapies that overcome chemoresistance in TNBC. We a...

Descripción completa

Detalles Bibliográficos
Autores principales: Panayotopoulou, Effrosini G., Müller, Anna-Katharina, Börries, Melanie, Busch, Hauke, Hu, Guohong, Lev, Sima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542169/
https://www.ncbi.nlm.nih.gov/pubmed/28187446
http://dx.doi.org/10.18632/oncotarget.15125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542169/
https://www.ncbi.nlm.nih.gov/pubmed/28187446
http://dx.doi.org/10.18632/oncotarget.15125

Ejemplares similares